Status:
NO_LONGER_AVAILABLE
Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer
Lead Sponsor:
I-Mab Biopharma US Limited
Conditions:
Cancer
Eligibility:
All Genders
Brief Summary
This expanded access protocol was designed to provide TJ004309 in combination with atezolizumab to the remaining three patients with advanced or metastatic cancer who plan to continue with treatment.
Eligibility Criteria
Inclusion
- Participation in the Tracon sponsored 4309ST101 or I-Mab sponsored TJ004309STM103 study and thought to have potential to derive clinical benefit from continued treatment in the opinion of the parent study investigator from dosing of TJ004309 in combination with atezolizumab.
- Willing or able to comply with study treatment and standard of care testing and procedures.
Exclusion
- Any unresolved ongoing toxicity or clinical event that would make continued treatment with TJ004309 inappropriate.
- Current treatment in another clinical study or treatment with other standard of care therapy.
- Currently pregnant.
- Current evidence of any condition (including medical, psychiatric or substance abuse disorder), therapy, or laboratory abnormality that might interfere with the patient's participation or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04869501
Last Update
April 28 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
2
HonorHealth Research Institute
Scottsdale, Arizona, United States, 85258
3
Arizona Oncology Associates, P.C.
Tucson, Arizona, United States, 85704